Ixazomib NEW
| Price | $41 | $96 | $129 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Ixazomib | CAS No.: 1072833-77-2 |
| Purity: 98.92% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Ixazomib |
| Description | Ixazomib (MLN2238) , a second generation, boron-containing peptide proteasome inhibitor (PI), inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome (IC50/Ki: 3.4/0.93 nM, in cell-free assays), also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites (IC50: 31/3500 nM). |
| Cell Research | Calu-6 cells are cultured in MEM containing 10% FBS and 1% penicillin/streptomycin and plated 1 day before the start of the experiment at 1 × 104 cells per well in a 384-well plate. For IC50 determinations, cells are treated with varying concentrations of Bortezomib or MLN2238 in DMSO (0.5% final, v/v) for 1 hour at 37 °C. For reversibility experiments, cells are treated with either 1 μM Bortezomib or MLN2238 for 30 minutes at 37 °C and then washed thrice in medium to remove the Bortezomib or MLN2238. Cells are incubated for an additional 4 hours at 37 °C, after which the medium is removed and replaced with fresh medium. (Only for Reference) |
| Kinase Assay | Kinase assay : Calu-6 cells are cultured in MEM containing 10% fetal bovine serum and 1% penicillin/streptomycin and plated 1 day before the start of the experiment at 1 × 104 cells per well in a 384-well plate. Proteasome activity is assessed by monitoring hydrolysis of the chymotrypsin-like substrate Suc-LLVY-aminoluciferin in the presence of luciferase using the Proteasome-Glo assay reagents according to the manufacturer's instructions. Luminescence is measured using a LEADseeker instrument. |
| In vitro | MLN2238 is a biologically active metabolite of MLN9708.MLN2238 and Bortezomib are both time-dependent reversible inhibitors of the proteasome, but the isolated half-life of the proteasomal effect of MLN2238 (18 min) is 6-fold faster compared with that of Bortezomib (110 min).The oncological efficacy of MLN2238 is higher than that of Bortezomib. MLN2238 is a nitrogen-terminally capped dipeptide leucine borate that inhibits the hydrolysis site of chymotrypsin-like enzymes in the 20S proteasome (IC50/Ki: 3.4/0.93 nM). At higher concentrations, MLN2238 also inhibited the caspase-like hydrolysis site (IC50: 31 nM) and the trypsin-like hydrolysis site (IC50: 3.5 μM) of the 20S proteasome.MLN2238 inhibited Calu-6 cells (IC50: 9.7 nM). |
| In vivo | MLN2238 is a biologically active metabolite of MLN9708.MLN2238 and Bortezomib are both time-dependent reversible inhibitors of the proteasome, but the isolated half-life of the proteasomal effect of MLN2238 (18 min) is 6-fold faster compared with that of Bortezomib (110 min).The oncological efficacy of MLN2238 is higher than that of Bortezomib. MLN2238 is a nitrogen-terminally capped dipeptide leucine borate that inhibits the hydrolysis site of chymotrypsin-like enzymes in the 20S proteasome (IC50/Ki: 3.4/0.93 nM). At higher concentrations, MLN2238 also inhibited the caspase-like hydrolysis site (IC50: 31 nM) and the trypsin-like hydrolysis site (IC50: 3.5 μM) of the 20S proteasome.MLN2238 inhibited Calu-6 cells (IC50: 9.7 nM). |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 55 mg/mL (152.34 mM) Ethanol : 9 mg/mL (24.92 mM) H2O : < 1 mg/mL (insoluble or slightly soluble) |
| Keywords | Inhibitor | Ixazomib | MLN-2238 | MLN 2238 | inhibit | Proteasome | Autophagy |
| Inhibitors Related | Stavudine | Sodium 4-phenylbutyrate | Hydroxychloroquine | Guanidine hydrochloride | Taurine | Curcumin | Oxyresveratrol | Paeonol | Naringin | Gefitinib |
| Related Compound Libraries | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $6.00/1KG |
VIP2Y
|
Henan Fengda Chemical Co., Ltd
|
2024-03-28 | |
| $0.00/1g |
VIP4Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2021-06-29 | |
| $2.00/1kg |
VIP7Y
|
Career Henan Chemical Co
|
2018-12-24 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY